10.08.2022 13:00:00

Innovid Reports Second Quarter 2022 Financial Results

  • Delivered 45% year-over-year revenue growth to $33.1 million on an as-reported basis
  • CTV accounted for 50% of the volume of all video impressions served
  • TV measurement accounted for 22% of all revenue
  • Launched InnovidXP – the first cross-platform TV measurement solution powered by ad serving data and creative personalization

NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Innovid Corp. (NYSE:CTV) (the "Company"), an independent advertising platform for delivery, personalization and measurement of converged TV across linear, connected TV (CTV) and digital, today announced financial results for the second quarter ended June 30, 2022.

Innovid. (PRNewsFoto/Innovid)

"Innovid delivered a strong second quarter with 45% year-over-year revenue growth, as CTV revenue continued to grow.  We achieved a critical milestone in our mission to fulfill the future of TV measurement with the launch of our converged TV measurement solution, InnovidXP, following the strategic acquisition of TVSquared" said Zvika Netter, Co-Founder and CEO. "Our joint teams and solutions have been realigned to introduce a unified first-to-market global cross-platform measurement solution, directly integrated with ad serving data. Measurement revenue grew significantly this past quarter and we expect InnovidXP to be a driving force for our growth story moving forward."

Second Quarter Financial Highlights:

(All comparisons are to the second quarter of 2021)

     • Revenue grew to $33.1 million for the combined business, reflecting an increase of 45% on an as-reported basis.
        ° TVSquared business grew 31% year-over-year and contributed $6.8 million in revenue, or 21% of revenue.
        ° CTV accounted for 47% of revenue, excluding TVSquared, up from 45% of revenue, demonstrating 20% year-over-year growth.
     • Net profit was $4.3 million or $0.03 per share.
     • Adjusted EBITDA* was negative $(1.7) million, representing (5)% adjusted EBITDA margin*.

Second Quarter Business Highlights:

     • CTV Volume Growth: CTV accounted for 50% of the volume of all video impressions served, up from 46% of volume in the second quarter of 2021, demonstrating 23% year-over-year growth.
     • Cross-Platform Measurement Expansion: Launched InnovidXP, the first unified cross-platform solution directly integrated with ad serving data and creative personalization, to solve cross-platform TV measurement globally.
        ° New Business: Measurement accounted for 22% of revenue in the second quarter supported by new clients including several leading multinational and national restaurant chains, an international design platform, and a worldwide employment platform. 
        ° Sell-Side Momentum: Expanded multi-year measurement partnership with Tubi, Fox's streaming service, demonstrating the power of InnovidXP for always-on incremental reach measurement across both Fox and Tubi.
     • New Client Wins: Closed multiple new clients across ad serving and personalization solutions including a multinational e-commerce company, a multinational travel company, and one of the largest U.S. health insurance providers. 
     • International Market Adoption: Increased international revenue by 51% year-over-year on an as-reported basis, through expanded measurement coverage outside the U.S.
     • Expanded Measurement Partnerships: Grew measurement footprint through strategic partnerships spanning programmatic, political, and international TV advertising.
        ° Programmatic CTV: Named a certified partner in Magnite's expanded measurement and attribution program, bringing currency optionality to programmatic CTV.
        ° Political TV Advertising: Partnered with leading ad intelligence data provider, AdImpact, to supply a unified view and real-time insights on reach, frequency, incremental reach, and outcomes, across linear and CTV.
        ° International Audience Measurement: Integrated within FreeWheel by Comcast's newly launched international AudienceXpress offering, allowing advertisers in Europe to buy premium TV advertising on an audience basis across all platforms.

Third Quarter 2022 Outlook

Innovid is providing the following financial guidance for the third quarter of 2022:
     • Revenue is expected to be in the range of $33 million to $35 million, reflecting 41% to 49% year-over-year growth on an as-reported basis, and 12% to 19% year-over-year growth on a pro forma basis when including TVSquared revenue.
     • Adjusted EBITDA* is expected to be in the range of negative $(2) million to break even.

Full Year 2022 Outlook

Innovid is providing the following updated financial guidance for the full year of 2022:
     • Revenue is expected to be in the range of $127 million to $132 million including TVSquared, a year-over-year increase of approximately 41% to 46% growth on an as-reported basis, and 17% to 22% year-over-year growth on a pro forma basis when including TVSquared revenue.
     • Total annual adjusted EBITDA* when accounting for the TVSquared acquisition, is expected to be negative $(6.0) million or higher.

Conference Call

Innovid will host a conference call and live webcast to discuss its second quarter 2022 financial results and business highlights today at 8:00 a.m. Eastern Time.  Speakers will include Zvika Netter, Co-founder and Chief Executive Officer, Tanya Andreev-Kaspin, Chief Financial Officer, and Tal Chalozin, Co-founder and Chief Technology Officer. To access the conference call, dial 877-407-3211 for the U.S. or Canada, or +1-201-389-0862 for international callers.  The webcast will be available live on the Investors section of the Company's website at https://investors.innovid.com/. Additionally, an archived webcast of the conference call will be made available on the Innovid website following the call. 

*This is a non-GAAP measure.  Refer to "Non-GAAP Measures" section below for additional information.

Non-GAAP Measures

Innovid prepares unaudited condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP"). Innovid also discloses and discusses non-GAAP financial measures such as Adjusted EBITDA and Adjusted EBITDA margin. Innovid believes that these measures are relevant and provide useful information to investors by providing a baseline for evaluation and comparing its operating performance against that of other companies in Innovid's industry. Adjusted EBITDA is defined as net income (loss) attributable to Innovid, excluding (1) depreciation and amortization, (2) stock-based compensation, (3) finance expense, net, (4) transaction related expenses, (5) acquisition related expenses, (6) taxes on income and (7) other one-time items. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by total revenue.

The non-GAAP financial measures that Innovid uses may not be comparable to similarly titled measures reported by other companies. Also, in the future, Innovid may disclose different non-GAAP financial measures in order to help its investors meaningfully evaluate and compare its results of operations to its previously reported results of operations or to those of other companies in Innovid's industry. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Innovid uses Adjusted EBITDA and Adjusted EBITDA margin as measures of operational efficiency to understand and evaluate its core business operations. Innovid believes these non-GAAP financial measures are useful to investors for period to period comparisons of its core business and for understanding and evaluating trends in its operating results on a consistent basis by excluding items that are not viewed as indicative of its core operating performance.

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as substitutes for an analysis of our results as reported under GAAP.

Innovid has provided a reconciliation of Adjusted EBITDA to net (loss) income and Adjusted EBITDA Margin to net (loss) income margin, the most directly comparable GAAP measures, for the historical period in the appendix hereto but is not able to provide a reconciliation of the projected non-GAAP measures for the second quarter of 2022 or the full-year 2022, without unreasonable effort, due to the unknown effect, timing and potential significance of: taxes on income in multiple jurisdictions, finance expenses including valuations, and purchase price allocation yet to be finalized. These items have in the past, and may in the future, significantly affect GAAP results in a particular period.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1996. The Company's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," "aim," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations regarding its future financial results and expected growth. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results, including Innovid's ability to raise financing in the future, success in retaining or recruiting officers, key employees or directors, changes in applicable laws or regulations, Innovid's ability to maintain and expand relationships with advertisers, decreases and/or changes in CTV audience viewership behavior, Innovid's ability to make the right investment decisions and to innovate and develop new solutions, the accuracy of Innovid's estimates of

market opportunity, forecasts of market growth and projections of future financial performance, the extent of investment required in Innovid's sales and marketing efforts, Innovid's ability to effectively manage its growth, the impact of the Covid-19 pandemic, the risk of continued inflation and other macroeconomic events, acquisition related risks, and other important factors discussed under the caption "Risk Factors" in Innovid's Annual Report on Form 10-K filed with the SEC on March 18, 2022, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC's website at www.sec.gov and the Investors Relations section of Innovid's website at investors.innovid.com. Most of these factors are outside the Company's control and are difficult to predict. The Company cautions not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

About Innovid

Innovid (NYSE:CTV) powers advertising delivery, personalization, measurement and outcomes across linear, CTV and digital for some of the world's largest brands. Through a global infrastructure that enables cross-platform ad serving, data-driven creative, and currency-grade measurement, Innovid offers its clients always-on intelligence to optimize advertising investment across channels, platforms, screens, and devices. Innovid is an independent platform that leads the market in converged TV innovation, through proprietary technology and exclusive partnerships designed to reimagine TV advertising. Headquartered in New York City, Innovid serves a global client base through offices across the Americas, Europe, and Asia Pacific. To learn more, visit innovid.com or follow us on LinkedIn or Twitter

Investor Relations:
Brinlea Johnson
ir@innovid.com

Media:
Chris Harihar
chris@crenshawcomm.com

 

INNOVID, CORP. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except stock and per stock data)



June 30, 2022


December 31, 2021


(Unaudited)



ASSETS




CURRENT ASSETS:




Cash and cash equivalents

$             44,024


$            156,696

Trade receivables, net (allowance for doubtful accounts of $69 and $81 at June 30, 2022 and December 31 2021, respectively)

43,553


35,422

Prepaid expenses and other current assets

5,247


3,131

Total current assets

92,824


195,249

NON-CURRENT ASSETS:




Long-term deposit

312


310

Long-term restricted deposits

411


462

Property and equipment, net

8,862


4,840

Goodwill

114,608


4,555

Intangible assets, net

35,135


Operating lease right of use asset

3,069


Other non-current assets

625


116

Total non-current assets

163,022


10,283

TOTAL ASSETS

$           255,846


$            205,532

LIABILITIES AND STOCKHOLDERS' EQUITY




CURRENT LIABILITIES:




Trade payables

3,661


5,026

Employees and payroll accruals

9,499


7,742

Accrued expenses and other current liabilities

4,662


3,082

Current portion of long-term debt

15,000


6,000

Lease liabilities - current portion

1,685


Total current liabilities

34,507


21,850

NON-CURRENT LIABILITIES:




Lease liabilities - non-current portion

2,464


Other non-current liabilities

3,831


3,455

Warrants liability

3,026


18,972

Total non-current liabilities

9,321


22,427

TOTAL LIABILITIES

43,828


44,277

COMMITMENTS AND CONTINGENT LIABILITIES




STOCKHOLDERS' EQUITY:




Common stock of $0.0001 par value - Authorized: 500,000,000 and 500,000,000 at June 30, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,411,715 and 119,017,380 at June 30, 2022 and December 31, 2021, respectively

13


12

Additional paid-in capital

347,630


293,719

Accumulated deficit

(135,625)


(132,476)

Total stockholders' equity

212,018


161,255

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$           255,846


$            205,532

 

INNOVID, CORP. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except stock and per stock data)



Three months ended
June 30,


Six months ended
June 30,


2022


2021


2022


2021


(Unaudited)


(Unaudited)


(Unaudited)


(Unaudited)

Revenues

$           33,088


$           22,842


$           58,950


$           40,855

Cost of revenues (1)

7,351


3,968


13,277


7,811

Research and development (1)

9,710


6,131


16,964


11,356

Sales and marketing (1)

14,320


8,105


24,671


14,677

General and administrative (1)

9,955


4,200


21,410


6,579

Depreciation and amortization

926


149


1,599


331

Operating (loss) profit

(9,174)


289


(18,971)


101

Finance expenses (income), net

(13,306)


1,602


(15,617)


3,171

Profit (loss) before taxes

4,132


(1,313)


(3,354)


(3,070)

Taxes on income (tax benefit)

(168)


346


(205)


525

Net profit (loss)

4,300


(1,659)


(3,149)


(3,595)









Accretion of preferred stock to redemption value


(21,076)



(44,804)

Net loss attributable to common stockholders

$              4,300


$          (22,735)


$            (3,149)


$          (48,399)

Net loss per stock attributable to common stockholders (2)








Basic

$                0.03


$              (1.33)


$              (0.02)


$              (2.85)

Diluted

$                0.03


$              (1.33)


$              (0.02)


$              (2.85)

Weighted-average number of stock used in computing net loss per stock attributable to common stockholders (2) 








Basic

132,152,652


17,116,586


128,220,893


16,956,139

Diluted

139,988,123


17,116,586


128,220,893


16,956,139



(1)

Exclusive of depreciation and amortization presented separately.

(2)

Prior period results have been adjusted to reflect the exchange of Innovid Inc's common stock for Innovid Corp's common stock at an exchange ratio of approximately 1.337 as a result of the Transaction.

 

INNOVID, CORP. AND ITS SUBSIDIARIES
CONDENSED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)
(In thousands, except stock data)



Temporary equity


Common stock


Treasury stock


Additional paid-in capital


Accumulated deficit


Total stockholders' equity (deficit)





Number


Amount


Number


Amount


Number


Amount







Balance as of December 31, 2020

73,690,340


$     86,997


16,275,609


$               2


1,914,328


$      (1,629)


$                 10


$        (48,113)


$        (49,730)




Accretion of preferred stock to redemption value


23,728






(586)


(23,142)


(23,728)




Stock-based compensation







280



280




Stock options exercised



761,697





306



306




Net loss








(1,936)


(1,936)




Balance as of March 31, 2021 (unaudited)

73,690,340


110,725


17,037,306


2


1,914,328


(1,629)


10


(73,191)


(74,808)




Accretion of preferred stock to redemption value


21,076






$          (1,500)


$        (19,576)


(21,076)




Stock-based compensation







$           1,440


$                 —


1,440




Stock options exercised



1,281,999





$                 61


$                 —


61




Net loss






$             —


$                 —


$          (1,659)


(1,659)




Balance as of June 30, 2021 (unaudited)

73,690,340


131,801


18,319,305


$               2


1,914,328


(1,629)


$                 11


$        (94,426)


$        (96,042)


























Temporary equity


Common stock


Treasury stock


Additional paid-in capital


Accumulated deficit


Total stockholders' equity





Number


Amount


Number


Amount


Number


Amount







Balance as of December 31, 2021



119,017,380


$             12




$       293,719


$      (132,476)


$       161,255




Common stock and equity awards issued for acquisition of TVS



11,549,465


1




47,151



47,152




Stock-based compensation







1,496



1,496




Stock options exercised



1,521,927





462



462




Net loss








(7,449)


(7,449)




Balance as of March 31, 2022 (unaudited)



132,088,772


13




342,828


(139,925)


202,916




Stock-based compensation







4,628



4,628




Stock options exercised



322,943





174



174




Net profit








4,300


4,300




Balance as of June 30, 2022 (unaudited)



132,411,715


$             13




$       347,630


$     (135,625)


$       212,018




 

INNOVID, CORP. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, except stock and per stock data) 



Six months ended June  30,


2022


2021

Cash flows from operating activities:

(Unaudited)


(Unaudited)

Net loss

$               (3,149)


$               (3,595)

Adjustments to reconcile net loss to net cash used in operating activities:




Depreciation and amortization

1,599


331

Stock-based compensation

5,634


1,720

Change in fair value of warrants

(15,946)


2,728

Changes in operating assets and liabilities




(Increase)/ decrease in trade receivables, net

(4,624)


2,605

Increase in prepaid expenses and other operating assets

(747)


(623)

Increase/ (decrease) in trade payables

(321)


238

Decrease in operating lease right of use assets

872


Increase/ (decrease) in employees and payroll accruals

1,044


184

Decrease in operating lease liabilities

(1,208)


Increase in accrued expenses and other operating liabilities

945


759

Net cash (used in)/ provided by operating activities

(15,901)


4,347

Cash flows from investing activities:




Acquisition of business, net of cash acquired

(99,568)


Internal use software capitalization

(3,516)


Purchase of property and equipment

(221)


(284)

Founders' note receivable


(459)

Decrease in deposits

32


(24)

Net cash used in investing activities

(103,273)


(767)

Cash flows from financing activities:




Repayment of acquisition liability


(126)

Proceeds from loans

9,000


Repayment of loans


(3,033)

Payment of SPAC merger transaction costs

(3,185)


Proceeds from exercise of options

636


367

Net cash (used in)/ provided by financing activities

6,451


(2,792)

Increase/ (decrease) in cash, cash equivalents and restricted cash

(112,723)


788

Cash, cash equivalents and restricted cash at the beginning of the period

157,158


16,092

Cash, cash equivalents and restricted cash at the end of the period

$              44,435


$              16,880

Supplemental disclosure of cash flows activities:




(1) Cash paid during the period for:




Income taxes paid, net of tax refunds

$                   363


$                    80

Interest

$                   137


$                   128

(2) Non-cash transactions:




Business combination consideration paid in stock

$              47,152


$                    —

Accretion of preferred stock to redemption value


$              44,804

Deferred offering cost included in accrued liabilities


$                1,640

Reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position




Cash and cash equivalents

44,024


16,441

Long-term restricted deposits

411


439

Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows

$              44,435


$              16,880

 

Key Metrics and Non-GAAP Financial Measures
Adjusted EBITDA


In addition to our results determined in accordance with US GAAP, we believe that certain non-GAAP financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin, are useful in evaluating our business. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by total revenue. The following table presents a reconciliation of Adjusted EBITDA, a non-GAAP financial measure, to the most directly comparable financial measure prepared in accordance with US GAAP.



Three months ended
June 30,


Six months ended
June 30,


2022


2021


2022


2021

Net profit (loss)

$    4,300


$   (1,659)


$ (3,149)


$ (3,595)

Net profit (loss) margin

13 %


(7) %


(5) %


(9) %

Depreciation and amortization

926


149


1,599


331

Stock-based compensation

4,138


1,440


5,730


1,720

Finance expense (income), net (a)

(13,306)


1,602


(15,617)


3,171

Transaction related expenses (b)

164



392


Acquisition related expenses (c)

768



4,971


Other (d)

1,518



1,610


Taxes on income

(168)


346


(205)


525

Adjusted EBITDA

$   (1,660)


$    1,878


$ (4,669)


$   2,152

Adjusted EBITDA margin

(5) %


8 %


(8) %


5 %











(a)

Finance expense (income), net consists primarily of remeasurement expense related to our foreign subsidiaries' monetary assets, liabilities and operating results, our interest expense and revaluation of our warrants. The unrealized gain from changes in the fair value of our warrants for the three months and six months period ended June 30, 2022 (unaudited) was $13.2 million and $15.9 million, respectively. The unrealized loss from changes in the fair value of our warrants for the three months and six months period ended June 30, 2021 (unaudited) was $1.4 million and $2.7 million, respectively.

(b)

Transaction related expenses consist of professional fees associated with the SPAC merger transaction and PIPE related SEC filings.

(c)

Acquisition related expenses consists of professional fees associated with the acquisition of TVS.

(d)

For the three months and six months ended June 30, 2022, "other" consists of exit costs for a former TVS employee, retention bonus expense for TVS employees and legal costs related to the Nielsen Claim.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/innovid-reports-second-quarter-2022-financial-results-301603162.html

SOURCE Innovid

Analysen zu Innovid Corp Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Innovid Corp Registered Shs 3,04 0,00% Innovid Corp Registered Shs